Cargando…

Reply: The long-term response to imatinib treatment of CML

Detalles Bibliográficos
Autor principal:	Michor, F
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360053/ http://dx.doi.org/10.1038/sj.bjc.6603604

Ejemplares similares

The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells
por: Zeng, Chengwu, et al.
Publicado: (2018)

Retention of CD34(+) CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors
por: Minami, Y, et al.
Publicado: (2012)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
por: Miranda, M B, et al.
Publicado: (2016)

Authors reply: Stevia: Long term data is lacking!
por: Purohit, Vikas, et al.
Publicado: (2018)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure
por: Enriquez, Virginia, et al.
Publicado: (2007)

Imatinib-Induced Psoriasis
por: Atalay, Figen, et al.
Publicado: (2013)

Imatinib-induced Gynecomastia
por: Gupta, Pragya, et al.
Publicado: (2019)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Eyebrow Whitening Induced by Imatinib
por: Yavasoglu, Irfan, et al.
Publicado: (2020)

Imatinib Mesylate-Induced Erythema Multiforme: Recurrence after Rechallenge with 200 mg/day Imatinib
por: Lee, Min Kyung, et al.
Publicado: (2015)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML
por: Krysiak, K, et al.
Publicado: (2016)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Reply: CPET for Long COVID-19
por: Mancini, Donna M., et al.
Publicado: (2022)

Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2014)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Letter to the Editor (reply to Souty C et al.): The causes of long‐term trends in the epidemiology of influenza
por: Caini, Saverio, et al.
Publicado: (2019)

A folate receptor 3 SNP promotes mitochondria‐induced clonogenicity of CML leukemia cells: Implications for treatment free remission
por: Shen, Na, et al.
Publicado: (2021)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy()
por: Aliano, Stefania, et al.
Publicado: (2013)

Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo
por: Li, Hui, et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Reply to: Comment on: ‘Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade'
por: Johnson, Philip, et al.
Publicado: (2016)

Reply to Comments on Relationship between Hypoalbuminemia on Admission and Long-term Mortality in Patients with Acute Decompensated Heart Failure
por: Yatsu, Shoichiro, et al.
Publicado: (2019)

Reply to “Digging deeper on the neurophysiological assessment in COVID-19 patients” and “Myopathy in acute and long-term COVID-19”
por: Hameed, Sajid, et al.
Publicado: (2022)

Reply
por: Pinto-Sanchez, M. Ines, et al.
Publicado: (2021)

Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting
por: Agarwal, Mohan B.
Publicado: (2014)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Response to Morrell et al's reply
por: Miller, Anthony B
Publicado: (2017)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Reply
por: Forrer, F., et al.
Publicado: (2007)

Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis
por: Tsuji, Masaaki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d0u82fc50m3j2islu2o574li3n